• Conditions and diseases

  • Blood and immune system •
  • Cancer •
  • Cardiovascular •
  • Central nervous system •
  • Digestive system •
  • Ear and nose •
  • Endocrine, nutritional and metabolic •
  • Eye •
  • Gynaecology, pregnancy and birth •
  • Infectious diseases •
  • Injuries, accidents and wounds •
  • Mental health and behavioural conditions •
  • Mouth and dental •
  • Musculoskeletal •
  • Respiratory •
  • Skin •
  • Urogenital

• Public health

  • Accidents and injuries •
  • Alcohol •
  • Behaviour change •
  • Cancer •
  • Cardiovascular disease •
  • Child health •
  • Child social care •
  • Chronic illness •
  • Diabetes •
  • Drugs •
  • Environmental health •
  • Infectious diseases •
  • Maternal health •
  • Mental health •
  • Non-communicable diseases •
  • Obesity and diet •
  • Occupational health •
  • Older people •
  • Physical activity •
  • Sexual health •
  • Smoking and tobacco •
  • Transport •
  • Vaccine preventable diseases •
  • Working with and involving communities

• Treatments, Procedures and Devices

  • Bones and joint surgery •
  • Cardiovascular surgery •
  • Cardiovascular system drug treatments •
  • Clinical devices •
  • Diagnostic imaging •
  • Diagnostic procedures •
  • Digestive tract and other abdominal organs surgery •
  • Drug treatments •
  • Endocrine system and breast surgery •
  • Eye surgery •
  • Nervous system surgery •
  • Radiotherapy •
  • Screening •
  • Surgical procedures •
  • Therapeutic procedures •
  • Tissue and organ donation •
  • Urogenital surgery

• Guidance by type

  • Clinical Guidelines •
  • Technology appraisals •
  • Public health guidance •
  • Diagnostics guidance •
  • Interventional procedures guidance •
  • Medical technologies guidance •
  • Cancer service guidance •
  • Quality standards

• Guidance by date

  • View the guidance by date published

About NICE guidance Close

Navigation

• NICE guidance

• Find guidance
• NICE Pathways
• Latest guidance
• Guidance by type
• Guidance in development
• How guidance is produced
• NICE guidance research recommendations
• Guidance for patients and public
• Other publications
• Patient safety solutions pilot
• Quality standards

Rheumatoid arthritis - tocilizumab

Tocilizumab for the treatment of rheumatoid arthritis

Status:	History
Expected date of issue:	August 2010
Referral date:	July 2008
Wave:	18
Process:	STA
Topic area: Musculoskeletal

Project team | Schedule | Stakeholders | Project history | Key documents

 

NICE project team

Executive Lead:	Andrew Dillon
Technical Lead:	Joanne Fielding & Christian Griffiths
Communications manager:	Tonya Gillis
Project manager:	Lori Farrar

Top

 

Provisional schedule

Closing date for invited submissions / evidence submission:	06 February 2009
1st appraisal committee meeting:	14 May 2009

Top

 

Consultees and commentators

Consultees Commentators (no right to submit or appeal) Manufacturers / Sponsors Roche Products (tocilizumab) Patient / Carer Groups Arthritis & Musculoskeletal Alliance (ARMA) Arthritis Care National Rheumatoid Arthritis Society Professional Groups British Health Professionals in Rheumatology British Society for Rheumatology Royal College of Nursing Royal College of Pathologists Royal College of Physicians Others Department of Health Welsh Assembly Government General Department of Health, Social Services and Public Safety for Northern Ireland NHS Quality Improvement Scotland Possible comparator manufacturer(s) Abbott Laboratories (adalimumab) AstraZeneca UK (chloroquine) GlaxoSmith Kline (azathioprine) Novartis (ciclosporin) Pfizer (methotrexate, sulfasalazine) Roche Products (rituximab) Sanofi Aventis (hydroxychloroquine, leflunomide, sodium aurothiomalate) Schering-Plough (infliximab) Wyeth Pharmaceuticals (etanercept) Relevant research Groups None Evidence Review Group West Midlands Health Technology Assessment Collaboration National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) Associated Guideline Groups None Associated Public Health Groups None

Top

 

Project history

Date Update 1 June 2009 The manufacturer of the drug have informed us that the date on which this drug will be launched in the UK has not been finalised and consequently the final price has not been formally announced. We therefore cannot release the decision agreed by the Committee and the evidence documentation related to the appraisal at this time. 25 September 2009 The appraisal has been reactivated because the price has now been formally registered. The price will shortly be made publicly available and  therefore the appraisal will recommence in line with the normal STA process. We will issuing a further update within the next week. 21 April 2010 Two appraisal committee meetings on this appraisal topic took place on 11 November 2009 and 10 February 2010. The next discussion on this appraisal topic is delayed until May 12 2010 Committee C meeting, (from the original schedule of 13 April 2010).  The reason for the delay is to allow sufficient time to consider the manufacturer (Roche) ACD response.

Top

 

Key documents

Rheumatoid arthritis - tocilizumab: final appraisal determination 01 July 2010 Rheumatoid arthritis - tocilizumab: appraisal consultation 3 04 March 2010 Rheumatoid arthritis - tocilizumab: appraisal consultation 2 16 December 2009 Rheumatoid arthritis - tocilizumab: appraisal consultation 01 October 2009 Rheumatoid arthritis - tocilizumab: final scope 27 November 2008 Rheumatoid arthritis - tocilizumab: response to consultee and commentator comments on the draft scope 27 November 2008 Rheumatoid arthritis - tocilizumab: response to consultee and commentator comments on the provisional matrix 27 November 2008

This page was last updated: 25 August 2010